The common animal vaccines at present are mainly applied in such mammals as pigs, cattle, sheep and bird species. In fact, fish and other aquatic products are also in demand for vaccines.
In 2009, the number of fattening pigs was over 640 million, that of flattening cattle over 40 million, and that of flattening poultries over 11 billion in China. In addition, large numbers of poultry eggs and over 12 million dairy cows were cultivated. In China, the breeding stock and fattened stock of pigs, cattle, sheep and other major domesticated animals essentially remain the growth rate of over 5%. It follows that the farmed animals requiring massive immunization are in huge number.
As the production of Chinese animal husbandry is changed from scattered mode to intensive and unified prevention mode, China is rapidly developing in the biological product industry based on veterinary vaccines. Currently, domestic veterinary vaccines are divided into FMD (Foot and mouth, abbr. FMD) vaccines, influenza vaccines, PRRS(Porcine Reproductive and Respiratory Syndrome, abbr. PRRS) vaccines, etc. As to the biotechnology, vaccines are divided into W vaccines, inactivated vaccines, live vaccines, influenza vaccines, etc.
In China, the animal vaccine industry is regarded as the gold mine of the capital market. The reason why the animal vaccine industry is expected lies in the large number of immune animals, far exceeding that of immune people; among up to hundreds of species of animal diseases, 70% are co-infected by human and animals-; the diseases spread more easily after the large-scale farming is improved, which raises the demand for vaccines; national subsidies and appropriation continue increasing; polyvalent vaccines replace the product up-gradation of monovalent vaccines; new products like pet vaccines amplify the vaccine market.
In 2009, the scale of China’s animal vaccine market was about CNY4.50 billion (USD740 million), increasing by more than 40% over 2008. It is predicted that in the next few years China’s vaccine industry will maintain a growth rate of 20-30% per year.
In general, with years of development of China’s veterinary vaccines, a relatively complete vaccine engineering system with complete vaccine product varieties has been formed. China, as one of the best stock farming countries, sees an increasing number of raised domestic animals, which has brought a greater rate of growth in the R&D of veterinary vaccines. With the increase of the intensification of livestock rearing, the vaccines related to diseases of respiratory tract, gastrointestinal tract and reproductive system have always been the focus of economic veterinary vaccines. With the increase of the intensification of livestock rearing and people's concern about food safety, the veterinary vaccine market will continue the steady growth trend.
This report has acquired a lot of valuable first-hand information through interviews and other means, and has quoted rich secondary sources of the Chinese Customs, trade associations, etc.
The following and more information can be acquired from this report:
- Government policy environment of Chinese animal vaccines
- Current situation of China’s animal vaccine market
- Current situation of China’s animal vaccine technology
- China's import and export situation of animal vaccines
- The development of China’s animal vaccine sub-industries
- Major enterprises of China’s animal vaccine industry and their operations
- Competition in China’s animal vaccine market
- Prospects for the development of China’s animal vaccine industry
The following persons are advised to buy this report:
- Animal vaccine manufacturers
- Animal vaccines trading enterprises
- Farming enterprises
- Animal vaccine research institutions
- Investors focusing on China's animal vaccine industry
For more please visit
http://www.bharatbook.com/detail.asp?id=91485&rt=Research-Report-on-Chinas-Animal-Vaccine-Industry-2011-2012.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Showing posts with label Vaccines. Show all posts
Showing posts with label Vaccines. Show all posts
Monday, December 27, 2010
Sunday, July 25, 2010
Conference on Vaccine Research & Innovation 2010
Key Speakers
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
Alexander von Gabain, Founder & Strategic Advisor to the Management and Supervisory Boards, Intercell
Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
Jean Marc Balloul, New Venture Development Director, Transgene
Lior Carmon, Founder & CEO, Vaxil Biotherapeutics
Conference Introduction
Vaccine Research & Innovation 2010
2nd – 3rd September 2010
Dear Colleague,
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction. According to recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing. Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event.
By attending this conference you will gain insights on:
• Overcoming challenges to cancer vaccine development
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution
Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital
Sponsorship and exhibition opportunities:
This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:
• Hosting a networking drinks reception
• Taking an exhibition space at the conference
• Advertising in the delegate documentation pack
• Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition possibilities for Vaccine Innovation and Cell Line Development Conference, please contact us:
Phone: +91 22 27578668
Email : raju@bharatbook.com
Day 1
Vaccine Research & Innovation 2010
Thursday 2nd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming
these challenges
• Engaging with regulators and contributing to the evolution of
regulatory framework
• Integrating your global regulatory strategy and product development
plan
Dr. David Kirke
Associate Director - Regulatory Affairs
ERA Consulting
10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early
Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology
11:30 Morning refreshments
11:50 High-throughput stable cell line generation
• Current-generation high-throughput sequencing
• Establishing new assays for high-throughput screening
• Optimised system for rapid generation of localisation and affinity purification-tagged mammalian stable cell lines
• Stabilisation of cell lines
12.30 Development of avian cell lines dedicated to vaccines manufacturing
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary vaccine
• Therapeutic proteins
Jean Marc Balloul
New Venture Development Director
Transgene
13:10 Networking lunch
14.10 Biologics cell line and process development
• Investigating a range of cell culture parameters
• Cell line selection and delivery system
• Vector redesign to improve cell line stability and clone selection
• Automation processes for cell line development
Karl Kreij
Cell Culture Scientist
Crucell
14:50 Manufacturing and purification strategies of conjugate vaccines
• Conjugate vaccine (peptide/chemical hapten) development, optimisation and production
• Production issues for conjugate vaccines
• Overview of the novel purification approaches
• Downstream processing parameters for purification
• Analysing the challenges associated with purification procedures
• Wide-scale adoption of disposable technologies
15:30 Afternoon refreshments
15:50 Safety monitoring in vaccine development and immunisation
• How can you know vaccines are safe?
• Challenges and risks with new vaccine introduction
• Surveillance through clinical trials to manufacturing processes
• Vaccine Adverse Event Reporting System (VAERS)
16:30 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials
Dr. Barbara Guinn
Cancer Sciences Division
University of Southampton
17:10 Closing remarks from the chair
17:20 Networking drinks
Take your discussions further and build new
relationships in a relaxed and informal setting.
Day 2
Vaccine Research & Innovation 2010
Friday 3rd September 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
•Immunological considerations and correlates
Alexander von Gabain
Founder & Strategic Advisor to the Management and Supervisory Boards
Intercell
10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response
Bror Morein
Department of Medical Sciences, Virology, Uppsala University
Chairman of the Scientific Advisory Board, Isconova
11:30 Morning refreshments
11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
Dr. Bassam Hallis
General Project Manager
Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Vaccine development & early clinical research
(Phase I)
• Phase I study design
• Managing sponsors
• Managing the vaccines
•Operational execution
Andrew Nolan
Senior Project Manager
Phase I Therapeutic Area Head – Vaccines
Quintiles
13:10 Networking lunch
14:10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.
Lior Carmon
Founder & CEO
Vaxil Biotherapeutics
14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido
Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
15:30 Afternoon refreshments
15:50 Challenges in adult immunisation
• What are disease areas in adult immunisation?
• Implementation of strategies to improve vaccination coverage
• Indentifying and minimising the impact on accessibility and affordability of adult vaccines
16.30 Accelerating new vaccine introduction in the developing world
• Meeting the challenges in introducing new vaccines: Logistics, supply and quality control issues
• Overcoming shortage and delays
• Good supply chain management practices for vaccine distribution
17:10 Chair’s closing remarks
17:20 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=133389&rt=Conference-on-Vaccine-Research-Innovation-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Subscribe to:
Posts (Atom)